Literature DB >> 20806975

Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.

Juliana de Saldanha da Gama Fischer1, Paulo Costa Carvalho, Clovis Orlando da Fonseca, Lujian Liao, Wim M Degrave, Maria da Gloria da Costa Carvalho, John R Yates, Gilberto B Domont.   

Abstract

Glioblastoma multiform (GBM) is by far the most malignant glioma. We have introduced a new treatment for GBMs that comprises the inhalation of a naturally occurring terpene with chemotherapeutic properties known as perillyl alcohol (POH). Clinical trial results on recurrent GBM patients showed that POH extends the average life by more than eight months, temporarily slows tumor growth, and in some cases even decreases tumor size. After approximately seven months, the tumor continues to grow and leads to a dismal prognosis. To investigate how these tumors become resistant to POH, we generated an A172 human glioblastoma cell culture tolerant to 0.06 mM of POH (A172r). We used Multidimensional Protein Identification Technology (MudPIT) to compare the protein expression profile of A172r cells to the established glioblastoma A172 cell line. Our results include a list of identified proteins unique to either the resistant or the nonresistant cell line. These proteins are related to cellular growth, negative apoptosis regulation, Ras pathway, and other key cellular functions that could be connected to the underlying mechanisms of resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20806975      PMCID: PMC3017632          DOI: 10.1021/pr100677g

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  49 in total

Review 1.  Role of the heat shock response and molecular chaperones in oncogenesis and cell death.

Authors:  C Jolly; R I Morimoto
Journal:  J Natl Cancer Inst       Date:  2000-10-04       Impact factor: 13.506

2.  Perillyl alcohol induces apoptosis in human glioblastoma multiforme cells.

Authors:  Janaína Fernandes; Clovis Orlando da Fonseca; Anselmo Teixeira; Cerli Rocha Gattass
Journal:  Oncol Rep       Date:  2005-05       Impact factor: 3.906

3.  Growth and metastasis of hypermotile, hyperinvasive cancer cells selected in vitro by rapid locomotion under various conditions.

Authors:  I A Grimstad
Journal:  Clin Exp Metastasis       Date:  1988 Jul-Aug       Impact factor: 5.150

4.  Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.

Authors:  Nathalie Auger; Joëlle Thillet; Krystell Wanherdrick; Ahmed Idbaih; Marie-Emmanuelle Legrier; Bernard Dutrillaux; Marc Sanson; Marie-France Poupon
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

5.  Natural resistance of human beta cells toward nitric oxide is mediated by heat shock protein 70.

Authors:  V Burkart; H Liu; K Bellmann; D Wissing; M Jäättela; M G Cavallo; P Pozzilli; K Briviba; H Kolb
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

6.  Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines.

Authors:  S Bardon; K Picard; P Martel
Journal:  Nutr Cancer       Date:  1998       Impact factor: 2.900

7.  Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.

Authors:  Ramasamy Jagadeeswaran; Hanna Surawska; Soundararajan Krishnaswamy; Varalakshmi Janamanchi; A Craig Mackinnon; Tanguy Y Seiwert; Sivakumar Loganathan; Rajani Kanteti; Trevor Reichman; Vidya Nallasura; Stuart Schwartz; Leonardo Faoro; Yi-Ching Wang; Luc Girard; Maria S Tretiakova; Salman Ahmed; Osvaldo Zumba; Lioubov Soulii; Vytas P Bindokas; Livia L Szeto; Gavin J Gordon; Raphael Bueno; David Sugarbaker; Mark W Lingen; Martin Sattler; Thomas Krausz; Wickii Vigneswaran; Viswanathan Natarajan; John Minna; Everett E Vokes; Mark K Ferguson; Aliya N Husain; Ravi Salgia
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

8.  A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.

Authors:  Howard H Bailey; Donna Levy; Linda S Harris; Julian C Schink; Francine Foss; Peter Beatty; Scott Wadler
Journal:  Gynecol Oncol       Date:  2002-06       Impact factor: 5.482

9.  GO Explorer: A gene-ontology tool to aid in the interpretation of shotgun proteomics data.

Authors:  Paulo C Carvalho; Juliana Sg Fischer; Emily I Chen; Gilberto B Domont; Maria Gc Carvalho; Wim M Degrave; John R Yates; Valmir C Barbosa
Journal:  Proteome Sci       Date:  2009-02-24       Impact factor: 2.480

10.  PatternLab for proteomics: a tool for differential shotgun proteomics.

Authors:  Paulo C Carvalho; Juliana S G Fischer; Emily I Chen; John R Yates; Valmir C Barbosa
Journal:  BMC Bioinformatics       Date:  2008-07-21       Impact factor: 3.169

View more
  10 in total

1.  Improving the TFold test for differential shotgun proteomics.

Authors:  Paulo C Carvalho; John R Yates; Valmir C Barbosa
Journal:  Bioinformatics       Date:  2012-04-26       Impact factor: 6.937

2.  Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.

Authors:  Patrick-Denis St-Coeur; Julie J Poitras; Miroslava Cuperlovic-Culf; Mohamed Touaibia; Pier Morin
Journal:  J Neurooncol       Date:  2015-08-28       Impact factor: 4.130

3.  Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.

Authors:  Karen A Oliveira; Tharine Dal-Cim; Flávia G Lopes; Fabiana K Ludka; Cláudia B Nedel; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

4.  Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.

Authors:  Karen A Oliveira; Tharine A Dal-Cim; Flávia G Lopes; Cláudia B Nedel; Carla Inês Tasca
Journal:  Purinergic Signal       Date:  2017-05-23       Impact factor: 3.765

Review 5.  Proteomics of gliomas: initial biomarker discovery and evolution of technology.

Authors:  Juliya Kalinina; Junmin Peng; James C Ritchie; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2011-09       Impact factor: 12.300

6.  Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy.

Authors:  Francisco das Chagas Abreu da Silveira; Bruno de Almeida Lopes; Clovis Orlando da Fonseca; Thereza Quirico-Santos; Izabel Christina Nunes de Palmer Paixão; Lidia Maria da Fonte de Amorim
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-06       Impact factor: 4.553

Review 7.  Simple, efficient and thorough shotgun proteomic analysis with PatternLab V.

Authors:  Marlon D M Santos; Diogo B Lima; Juliana S G Fischer; Milan A Clasen; Louise U Kurt; Amanda Caroline Camillo-Andrade; Leandro C Monteiro; Priscila F de Aquino; Ana G C Neves-Ferreira; Richard H Valente; Monique R O Trugilho; Giselle V F Brunoro; Tatiana A C B Souza; Renata M Santos; Michel Batista; Fabio C Gozzo; Rosario Durán; John R Yates; Valmir C Barbosa; Paulo C Carvalho
Journal:  Nat Protoc       Date:  2022-04-11       Impact factor: 17.021

8.  Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.

Authors:  Stella Sun; T S Wong; X Q Zhang; Jenny K S Pu; Nikki P Lee; Philip J R Day; Gloria K B Ng; W M Lui; Gilberto K K Leung
Journal:  J Neurooncol       Date:  2011-10-07       Impact factor: 4.130

9.  Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.

Authors:  Maria Wiese; Feda H Hamdan; Klaudia Kubiak; Christopher Diederichs; Gerrit H Gielen; Gunther Nussbaumer; Angel M Carcaboso; Esther Hulleman; Steven A Johnsen; Christof M Kramm
Journal:  Cell Death Dis       Date:  2020-08-21       Impact factor: 8.469

10.  Chemical Composition, Antioxidant, Antimicrobial and Cytotoxic Activities of Essential Oil from Premna microphylla Turczaninow.

Authors:  Han-Yu Zhang; Yang Gao; Peng-Xiang Lai
Journal:  Molecules       Date:  2017-02-28       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.